These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 30052921)

  • 21. Liraglutide vs. lixisenatide in obese type 2 diabetes mellitus patients: What effect should we expect in routine clinical practice?
    Moreno-Fernandez J; Garcia-Seco JA; Seco Segura AM; Garcia-Seco F; Rozas Moreno PJ; Aguirre Sanchez-Covisa M
    Prim Care Diabetes; 2020 Feb; 14(1):68-74. PubMed ID: 31171461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
    Barnett AH; Arnoldini S; Hunt B; Subramanian G; Hoxer CS
    Diabetes Obes Metab; 2018 Aug; 20(8):1921-1927. PubMed ID: 29652101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus.
    Guarnotta V; Bianco MJ; Vigneri E; Panto' F; Lo Sasso B; Ciaccio M; Pizzolanti G; Giordano C
    Nutr Metab Cardiovasc Dis; 2021 Oct; 31(11):3193-3201. PubMed ID: 34518091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.
    Burcelin R; Gourdy P
    Obes Rev; 2017 Jan; 18(1):86-98. PubMed ID: 27636208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Beyond glycemic control in type 2 diabetes. Promises and gambles of therapy with glucagon-like peptide-1 receptor agonists].
    Mannucci E
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):3-4. PubMed ID: 22158420
    [No Abstract]   [Full Text] [Related]  

  • 26. Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes.
    Heuvelman VD; Van Raalte DH; Smits MM
    Cardiovasc Res; 2020 Apr; 116(5):916-930. PubMed ID: 31825468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.
    Tzotzas T; Karras SN; Katsiki N
    Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.
    Boye KS; Riddle MC; Gerstein HC; Mody R; Garcia-Perez LE; Karanikas CA; Lage MJ; Riesmeyer JS; Lakshmanan MC
    Diabetes Obes Metab; 2019 Jun; 21(6):1299-1304. PubMed ID: 30714309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?
    Updike WH; Pane O; Franks R; Saber F; Abdeen F; Balazy DD; Carris NW
    Drugs; 2021 Jun; 81(8):881-893. PubMed ID: 33929717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
    Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GLP-1-based therapies to boost autophagy in cardiometabolic patients: From experimental evidence to clinical trials.
    Costantino S; Paneni F
    Vascul Pharmacol; 2019 Apr; 115():64-68. PubMed ID: 30926561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient initiation and maintenance of GLP-1 RAs for treatment of obesity.
    Patel D; Smith A
    Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1193-1204. PubMed ID: 34231442
    [No Abstract]   [Full Text] [Related]  

  • 33. GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials.
    Jia X; Alam M; Ye Y; Bajaj M; Birnbaum Y
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):65-72. PubMed ID: 29445896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
    Edelman SV
    J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular safety of liraglutide for the treatment of type 2 diabetes.
    Chudleigh RA; Bain S
    Expert Opin Drug Saf; 2017 May; 16(5):627-635. PubMed ID: 28387138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Practical guidance for use of oral semaglutide in primary care: a narrative review.
    Morales J; Shubrook JH; Skolnik N
    Postgrad Med; 2020 Nov; 132(8):687-696. PubMed ID: 32643514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.
    Mann JFE; Fonseca VA; Poulter NR; Raz I; Idorn T; Rasmussen S; von Scholten BJ; Mosenzon O;
    Clin J Am Soc Nephrol; 2020 Apr; 15(4):465-473. PubMed ID: 32132141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity.
    Lin CH; Shao L; Zhang YM; Tu YJ; Zhang Y; Tomlinson B; Chan P; Liu Z
    Expert Opin Pharmacother; 2020 Feb; 21(3):275-285. PubMed ID: 31790314
    [No Abstract]   [Full Text] [Related]  

  • 40. The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.
    Guo X; Zhou Z; Lyu X; Xu H; Zhu H; Pan H; Wang L; Yang H; Gong F
    Horm Metab Res; 2022 Jul; 54(7):458-471. PubMed ID: 35512849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.